Novonesis A/S Class B

As of June 30, 2026, Novonesis A/S Class B carries a market capitalization of 25.56B, placing it among publicly traded companies globally. Its enterprise value stands at 28.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novonesis A/S Class B's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Novonesis A/S Class B has 466.25M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Novonesis A/S Class B maintains a current ratio of 1.74, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novonesis A/S Class B recorded 137.60M in income tax expense.

As of the close on October 22, 2026, Novonesis A/S Class B's stock has gained approximately 13.63% over the past 52 weeks. The 50-day moving average sits at 58.61, while the 200-day moving average is 53.87.

As of June 30, 2026, Novonesis A/S Class B holds 313.60M in cash and equivalents against 3.07B in total debt, resulting in a net debt position of 2.52B. Total book value stands at 11.15B, with working capital of 883.90M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novonesis A/S Class B paid dividends of 0.57 per share.

Novonesis A/S Class B's most recent stock split took place on November 28, 2011 with a 1:5 split ratio.